|
1
|
Ding SJ, Li Y, Tan YX, Jiang MR, Tian B,
Liu YK, Shao XX, Ye SL, Wu JR, Zeng R, et al: From proteomic
analysis to clinical significance: overexpression of cytokeratin 19
correlates with hepatocellular carcinoma metastasis. Mol Cell
Proteomics. 3:73–81. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Altekruse SF, McGlynn KA and Reichman ME:
Hepatocellular carcinoma incidence, mortality, and survival trends
in the United States from 1975 to 2005. J Clin Oncol. 27:1485–1491.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
El-Serag HB and Rudolph KL: Hepatocellular
carcinoma: epidemiology and molecular carcinogenesis.
Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar
|
|
5
|
Venook AP, Papandreou C, Furuse J and de
Guevara LL: The incidence and epidemiology of hepatocellular
carcinoma: a global and regional perspective. Oncologist. 15(Suppl
4): 5–13. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Llovet JM, Burroughs A and Bruix J:
Hepatocellular carcinoma. Lancet. 362:1907–1917. 2003. View Article : Google Scholar
|
|
7
|
Wu L, Peng CW, Hou JX, Zhang YH, Chen C,
Chen LD and Li Y: Coronin-1C is a novel biomarker for
hepatocellular carcinoma invasive progression identified by
proteomics analysis and clinical validation. J Exp Clin Cancer Res.
24: 29:172010.PubMed/NCBI
|
|
8
|
Ai J, Huang H, Lv X, Tang Z, Chen M, Chen
T, Duan W, Sun H, Li Q, Tan R, et al: FLNA and PGK1 are two
potential markers for progression in hepatocellular carcinoma. Cell
Physiol Biochem. 27:207–216. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tian J, Tang ZY, Ye SL, Liu YK, Lin ZY,
Chen J and Xue Q: New human hepatocellular carcinoma (HCC) cell
line with highly metastatic potential (MHCC97) and its expressions
of the factors associated with metastasis. Br J Cancer. 81:814–821.
1999. View Article : Google Scholar
|
|
10
|
Li Y, Tang ZY, Ye SL, Liu YK, Chen J, Xue
Q, Chen J, Gao DM and Bao WH: Establishment of cell clones with
different metastatic potential from the metastatic hepatocellular
carcinoma cell line MHCC97. World J Gastroenterol. 7:630–636.
2001.PubMed/NCBI
|
|
11
|
Li Y, Tang Y, Ye L, Liu B, Liu K, Chen J
and Xue Q: Establishment of a hepatocellular carcinoma cell line
with unique metastatic characteristics through in vivo selection
and screening for metastasis-related genes through cDNA microarray.
J Cancer Res Clin Oncol. 129:43–51. 2003.
|
|
12
|
Li Y, Tian B, Yang J, Zhao L, Wu X, Ye SL,
Liu YK and Tang ZY: Stepwise metastatic human hepatocellular
carcinoma cell model system with multiple metastatic potentials
established through consecutive in vivo selection and studies on
metastatic characteristics. J Cancer Res Clin Oncol. 130:460–468.
2004.
|
|
13
|
Li Y, Tang ZY, Tian B, Ye SL, Qin LX, Xue
Q and Sun RX: Serum CYFRA 21–1 level reflects hepatocellular
carcinoma metastasis: study in nude mice model and clinical
patients. J Cancer Res Clin Oncol. 132:515–520. 2006.
|
|
14
|
Holly MK, Dear JW, Hu X, Schechter AN,
Gladwin MT, Hewitt SM, Yuen PS and Star RA: Biomarker and
drug-target discovery using proteomics in a new rat model of
sepsis-induced acute renal failure. Kidney Int. 70:496–506.
2006.PubMed/NCBI
|
|
15
|
Kabuyama Y, Resing KA and Ahn NG: Applying
proteomics to signaling networks. Curr Opin Genet Dev. 14:492–498.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang K, Ye C, Zhou Q, Zheng R, Lv X, Chen
Y, Hu Z, Guo H, Zhang Z, Wang Y, Tan R and Liu Y: PKD1 inhibits
cancer cells migration and invasion via Wnt signaling pathway in
vitro. Cell Biochem Funct. 25:767–774. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
El-Serag HB: Epidemiology of viral
hepatitis and hepatocellular carcinoma. Gastroenterology.
142:1264–1273. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lok AS, Sterling RK, Everhart JE, et al;
HALT-C Trial Group. Des-Gamma-carboxy prothrombin and
alpha-fetoprotein as biomarkers for the early dection of
hepatocellular carcinoma. Gastroenterology. 138:493–502. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Feng Y and Walsh CA: The many faces of
filamin: a versatile molecular scaffold for cell motility and
signalling. Nat Cell Biol. 6:1034–1038. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bedolla RG, Wang Y, Asuncion A, Chamie K,
Siddiqui S, Mudryj MM, Prihoda TJ, Siddiqui J, Chinnaiyan AM, Mehra
R, de Vere White RW and Ghosh PM: Nuclear versus cytoplasmic
localization of filamin A in prostate cancer: immunohistochemical
correlation with metastases. Clin Cancer Res. 15:788–796. 2009.
View Article : Google Scholar
|
|
21
|
Bourguignon LY, Gilad E and Peyrollier K:
Heregulin-mediated ErbB2-ERK signaling activates hyaluronan
synthases leading to CD44-dependent ovarian tumor cell growth and
migration. J Biol Chem. 282:19426–19441. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Dayan F, Roux D, Brahimi-Horn MC,
Pouyssegur J and Mazure NM: The oxygen sensor factor-inhibiting
hypoxia-inducible factor-1 controls expression of distinct genes
through the bifunctional transcriptional character of
hypoxia-inducible factor-1alpha. Cancer Res. 66:3688–3698. 2006.
View Article : Google Scholar
|
|
23
|
González V and Hurley LH: The C-terminus
of nucleolin promotes the formation of the c-MYC G-quadruplex and
inhibits c-MYC promoter activity. Biochemistry. 49:9706–9714.
2010.PubMed/NCBI
|
|
24
|
Abdelmohsen K and Gorospe M: RNA-binding
protein nucleolin in disease. RNA Biol. 9:799–808. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tajrishi MM, Tuteja R and Tuteja N:
Nucleolin: the most abundant multifunctional phosphoprotein of
nucleolus. Commun Integr Biol. 4:267–275. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Parada CA and Roeder RG: A novel RNA
polymerase II-containing complex potentiates Tat-enhanced HIV-1
transcription. Embo J. 18:3688–3701. 1999. View Article : Google Scholar : PubMed/NCBI
|
